This article may require cleanup to meet Wikipedia's quality standards. Please improve this article if you can. (August 2008)

Actinic keratosis Classification and external resources
ICD-10	L57.0
ICD-9	702.0

Actinic keratosis (also called solar keratosis, or AK) is a premalignant condition of thick, scaly, or crusty patches of skin. It is more common in fair-skinned people, especially those who are frequently exposed to the sun, as it is usually accompanied by solar damage. Since some of these pre-cancers progress to squamous cell carcinoma, they should be treated.

When skin is exposed to the sun constantly, thick, scaly, or crusty bumps appear. The scaly or crusty part of the bump is dry and rough. The growths start out as flat scaly areas, and later grow into a tough, wart-like area.

An actinic keratosis site commonly ranges between 2 and 6 millimeters in size, and can be dark or light, tan, pink, red, a combination of all these, or have the same pigment as the surrounding skin. It may appear on any sun-exposed area, such as the face, ears, neck, scalp, chest, backs of hands, forearms, or lips.

Prevention

Preventive measures recommended for AK are similar to those for skin cancer:

• Not staying in the sun for long periods of time without protection (e.g.:sunscreen, clothing, hats).
• Frequently applying powerful sunscreens with SPF ratings greater than 15 and that also block both UVA and UVB light.
• Using sunscreen even in winter sun exposure.
• Wearing sun protective clothing such as hats, long-sleeved shirts, long skirts, or pants.
• Avoiding sun exposure during noon hours is very helpful because ultraviolet light is the most powerful at that time.

Diagnosis

Doctors can usually identify AK by doing a thorough examination. A biopsy may be necessary when the keratosis is large and/or thick, to make sure that the bump is a keratosis and not a skin cancer. Seborrheic keratoses are other bumps that appear in groups like the actinic keratosis but are not caused by sun exposure, and are not related to skin cancers. Seborrheic keratoses may be mistaken for an actinic keratosis.

Treatment

Various modalities are employed in the treatment of actinic keratosis:

• Cryosurgery, e.g. with liquid nitrogen, by "freezing off" the AKs.
• 5-fluorouracil (a chemotherapy agent): a cream that contains this medication causes AKs to become red and inflamed before they fall off.
• Photodynamic therapy: this new therapy involves injecting a chemical into the bloodstream, which makes AKs more sensitive to any form of light.
• Laser , notably CO₂ and Er:YAG lasers. A Laser resurfacing technique is often used with diffuse AKs.
• Electrocautery: burning off AKs with electricity.
• Immunotherapy: topical treatment with imiquimod (Aldara), an immune enhancing agent
• Crocodile oil: is available as a skin balm and has been used successfully as is a natural remedy.
• Different forms of surgery.

Regular follow-up after treatment is advised by many doctors. The regular checks are to make sure new bumps have not developed and that old ones haven't become thicker and/or have skin disease.

Experimental treatments

In 2007, Australia biopharmaceutical company Clinuvel Pharmaceuticals Limited began clinical trials with a melanocyte-stimulating hormone called melanotan (known by the International Nonproprietary Name afamelanotide, formerly CUV1647)^[1] for actinic keratosis in organ transplant patients.^[2][3]
Another Australian biopharmaceutical company Peplin ^[4] is also developing a topical treatment for actinic keratosis. Formed in 1998 they are currently developing PEP005, which is the first in a new class of compounds and which is derived from Euphorbia peplus, or E. peplus, a rapidly growing, readily-available plant, commonly referred to as petty spurge or radium weed. The sap of E. peplus has a long history of traditional use for a variety of conditions, including the topical self-treatment of various skin disorders, such as skin cancer and pre-cancerous skin lesions. The company has recently redomiciled to the USA and is about to enter phase III trials with PEP005.

External links

• American Academy of Dermatology
• American Osteopathic College of Dermatology
• National Library of Medicine and the National Institute of Health
• Actinic Keratosis photo library at Dermnet
• Medicinenet's article on Actinic Keratosis
• Information on Actinic Keratosis from The Skin Cancer Foundation

References

• Abel EA (1989). "Cutaneous manifestations of immunosuppression in organ transplant recipients". J Am Acad Dermatol 21 (2 Pt 1): 167–79. PMID 2671063. 
• Fitzpatrick TB (1988). "The validity and practicality of sun-reactive skin types I through VI". Arch Dermatol 124 (6): 869–71. doi:10.1001/archderm.124.6.869. PMID 3377516. 
• Glogau RG (2000). "The risk of progression to invasive disease". J Am Acad Dermatol 42 (1 Pt 2): 23–4. doi:10.1067/mjd.2000.103339. PMID 10607353. 
• Gordon D, Silverstone H. (1969). "The biologic effects of ultraviolet radiation", in Ubach F, editor: The Biologic Effects of Ultraviolet Radiation. Oxford (UK): Pergamon Press, p. 625. 
• Lookingbill DP, Lookingbill GL, Leppard B (1995). "Actinic damage and skin cancer in albinos in northern Tanzania: findings in 164 patients enrolled in an outreach skin care program". J Am Acad Dermatol 32 (4): 653–8. doi:10.1016/0190-9622(95)90352-6. PMID 7896957. 
• Marshall V (1974). "Premalignant and malignant skin tumours in immunosuppressed patients". Transplantation 17 (3): 272–5. doi:10.1097/00007890-197403000-00006. PMID 4592184. 
• Scotto J, Fears TR, Fraumeni JF. Incidence of nonmelanoma skin cancer in the United States. Publication No (NIH) 82-2433. Washington, DC: US Dept Health and Human Services; 1983.